Gadobenate dimeglumine (MultiHance) for magnetic resonance angiography: review of the literature.
Although limited in number, reports describing the use of Gd-BOPTA for 3D CE-MRA reveal that this agent is safe, well tolerated and effective for CE-MRA at doses up to 0.3 mmol/kg bodyweight. The use of Gd-BOPTA leads to additional diagnostically relevant information comparable to that attainable with conventional DSA and superior to that on non-enhanced MRA in most arterial territories. In studies in which Gd-BOPTA is compared at equal dose with other gadolinium-based MR contrast agents, Gd-BOPTA has consistently shown significantly better quantitative and qualitative performance. Thus, Gd-BOPTA can be considered to have a very favorable risk/benefit ratio for MRA. In summary, it is likely the documented superiority of Gd-BOPTA for MR angiography will lead to its broad usage for this indication wherever the agent becomes available.
Goyen
M
M
Department of Diagnostic and Interventional Radiology, University Hospital Essen, Essen, Germany.
Debatin
J F
JF
D016893:Carotid Stenosis / Q000175:diagnosis*; D003287:Contrast Media; D005682:Gadolinium; D006801:Humans; D018810:Magnetic Resonance Angiography / Q000379:methods; D008536:Meglumine / Q000031:analogs & derivatives*; D009942:Organometallic Compounds; D016491:Peripheral Vascular Diseases / Q000175:diagnosis*; D011651:Pulmonary Artery / Q000473:pathology; D012680:Sensitivity and Specificity
D003287:Contrast Media; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine; D005682:Gadolinium